Evidence map›Paper›PMID 34779227›Full record

ArticleAIDS research and human retroviruses2022

Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV.

Robert J Schieffer, Ewa Bryndza Tfaily, Richard D'Aquila, George J Greene, Alex Carballo-Diéguez, Rebecca Giguere, Christine Tagliaferri Rael, Patrick F Kiser, Thomas J Hope

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Robert J SchiefferNorthwestern University, Kellogg School of Management, Evanston, Illinois, USA.
Ewa Bryndza TfailyDepartment of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Richard D'AquilaDivision of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
George J GreeneDepartment of Medical Social Sciences, Institute for Sexual Gender Minority Health and Wellbeing, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Alex Carballo-DiéguezHIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, New York, New York, USA.
Rebecca GiguereHIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, New York, New York, USA.
Christine Tagliaferri RaelHIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, New York, New York, USA.
Patrick F KiserDepartment of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.
Thomas J HopeDepartment of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-7183-8319
Northwestern University · USNew York Psychoanalytic Society and Institute · US

Funding

Sustained Long Acting Prevention Against HIV Program OperationUM1AI120184 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HOPE, THOMAS, KISER, PATRICK FRANKLIN · 2015 to 2019
$17.9M
Supplement: Developing Tailored Delivery and Adherence Interventions for use of Long-Acting Biomedical HIV Prevention Strategies by Transgender WomenK01MH115785 · NIMH · UNIVERSITY OF COLORADO DENVER · PI RAEL, CHRISTINE TAGLIAFERRI · 2018 to 2022
$767k
NIAID NIH HHS UM1 AI120184NIMH NIH HHS K01 MH115785
6 · The paper itself

Abstract

Long-acting delivery modalities of HIV pre-exposure prophylaxis (PrEP), such as subdermal implants, are in development. To facilitate end-user uptake and sustained use, it is critical to understand potential consumers' and physician prescribers' preferences about, interest in, and relative importance of different implant features. The ordered identification of these key attributes allows implant developers to incorporate this feedback into product design, which theoretically improves acceptability, feasibility, and user experience with the device. In this study,

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesHomosexuality, MaleHumansMalePatient Acceptance of Health CareSurveys and QuestionnairesAnti-HIV Agentsconjoint analysisHIV preventionMSMPrEP

Identifiers

PMID34779227
PMCPMC9048179
OpenAlexW3214498116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.